Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

• Main Authors: Silvia Pelligra (Author), Natalia Buza (Author), Pei Hui (Author), Stefania Bellone (Author), Burak Zeybek (Author), Elena Ratner (Author), Peter E. Schwartz (Author), Giovanni Scambia (Author), Alessandro D. Santin (Author)
• Format: Book
• Published: Elsevier, 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment...